Trial Profile

A phase 2a study to evaluate safety, tolerability and pharmacokinetics of IKT-148009 in patients with multiple systemic atrophy (MSA)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Jun 2024 According to Inhibikase Therapeutics media release, The National Institute of Neurological Diseases and Stroke (NINDS) is initiating a new funding mechanism for clinical development in neuroscience beginning June, 2024. Through this new program, termed the Other Transaction Authority (OTA), the Company is seeking to support its Phase 2 "202 Trial' in MSA trial using a dedicated U.S. trial network set-up by the Institute.
19 Dec 2023 According to Inhibikase Therapeutics media release, the company plan to submit complementary regulatory documents for risvodetinib to European Union authorities in 2024.
04 Oct 2023 According to Inhibikase Therapeutics media release, the company received IND clearance in March 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com